Germline and somatic NF1 alterations are linked to increased HER2 expression in breast cancer

Academic Article


  • NF1 germline mutation predisposes to breast cancer. NF1 mutations have also been proposed as oncogenic drivers in sporadic breast cancers. To understand the genomic and histologic characteristics of these breast cancers, we analyzed the tumors with NF1 germline mutations and also examined the genomic and proteomic profiles of unselected tumors. Among 14 breast cancer specimens from 13 women affected with neuro-fibromatosis type 1 (NF1), 9 samples (NF þ BrCa) underwent genomic copy number (CN) and targeted sequencing analysis. Mutations of NF1 were identified in two samples and TP53 were in three. No mutation was detected in ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, NBN, PALB2, PTEN, RAD50, and STK11. HER2 (ErbB2) overexpression was detected by IHC in 69.2% (9/13) of the tumors. CN gain/amplification of ERBB2 was detected in 4 of 9 with DNA analysis. By evaluating HER2 expression and NF1 alterations in unselected invasive breast cancers in TCGA datasets, we discovered that among samples with ERBB2 CN gain/amplification, the HER2 mRNA and protein expression were much more pronounced in NF1-mutated/deleted samples in comparison with NF1-unaltered samples. This finding suggests a synergistic interplay between these two genes, potentially driving the development of breast cancer harboring NF1 mutation and ERBB2 CN gain/amplification. NF1 gene loss of heterozygosity was observed in 4 of 9 NF þ BrCa samples. CDK4 appeared to have more CN gain in NF þ BrCa and exhibited increased mRNA expression in TCGA NF1-altered samples.
  • Published In

    Digital Object Identifier (doi)

    Author List

  • Wang X; Kallionpaa RA; Gonzales PR; Chitale DA; Tousignant RN; Crowley JP; Chen Z; Yoder SJ; Blakeley JO; Acosta MT
  • Start Page

  • 655
  • End Page

  • 663
  • Volume

  • 11
  • Issue

  • 10